2021年3月3日 · CheckMate 9ER is a phase 3, randomized, open-label trial of nivolumab combined with cabozantinib as compared with sunitinib monotherapy. ... 10.6 to 30.6), the …

2024年1月29日 · Background: N+C demonstrated superior progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) vs S in patients (pts) with previously …

2022年1月12日 · CheckMate 9ER was an open-label, randomised, phase 3 trial done in 125 cancer centres, urology centres, and hospitals across 18 countries (a list of sites is included …

2021年3月4日 · Nivolumab plus cabozantinib had significant benefits over sunitinib with respect to progression-free survival, overall survival, and likelihood of response in patients with …

2025年2月17日 · About CheckMate -9ER CheckMate -9ER is an open-label, randomized, multi-national phase 3 trial evaluating patients with previously untreated advanced or metastatic …

2023年2月21日 · In this exploratory post hoc analysis we conducted an analysis of anti–PD-1 (N) + anti-VEGF (C) v S by assessing potential predictive biomarkers for efficacy in CheckMate …

patient population.3-10 As ICI combination therapy is known to be associated with durable response in this disease setting, longer follow-ups are important to assess the durability of …

Background: In the CheckMate 9ER trial, patients with advanced renal cell carcinoma who received first-line nivolumab plus cabozantinib had significantly better progression-free survival …

2021年4月10日 · Results of the CheckMate 9ER phase III trial showed significantly improved patient-reported outcomes in quality of life for first-line treatment with nivolumab plus …

Background: In the primary analysis of CheckMate 9ER, nivolumab plus cabozantinib showed superior progression-free survival, overall survival, and objective response over sunitinib in …